Evolución y pronóstico del carcinoma in situ vesical tratado con bcg
- 1 January 1999
- journal article
- abstracts
- Published by Elsevier BV in Actas Urológicas Españolas (English Edition)
- Vol. 23 (8), 670-680
- https://doi.org/10.1016/s0210-4806(99)72349-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor.European Urology, 1998
- Tumour progression and survival in patients with T1G3 bladder tumours: 15‐year outcomeBritish Journal of Urology, 1997
- Long-Term Efficacy of Intravesical Bacillus Calmette-Guerin for Carcinoma in Situ: Relationship of Progression to Histological Response and p53 Nuclear AccumulationJournal of Urology, 1997
- Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): Its impact on managementUrology, 1997
- BCG Update: Intravesical TherapyEuropean Urology, 1997
- In situ transitional cell carcinoma involvement of prostatic urethra: Bacillus calmette-guérin therapy without previous transurethral resection of the prostateUrology, 1996
- Carcinoma in Situ of the BladderJournal of Urology, 1995
- Analysis of early failures after intravesical instillation therapy with bacille Calmette‐Guerin for carcinoma in situ of the bladderBritish Journal of Urology, 1995
- Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: A 10-Year FollowupJournal of Urology, 1992
- Histological Study of Vesical Urothelium Intervening Between Gross Neoplasms in Total CystectomyJournal of Urology, 1952